FK506 Antibody (FK1) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NB100-62571
Key Product Details
Species Reactivity
Non-species specific
Applications
ELISA
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgM Clone # FK1
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
FK-506-BSA conjugate
Specificity
NB100-62571 detects FK-506, a macrolide with similar but more potent immunosuppressant activity than cyclosporine. It is a 23-membered lactone produced by the bacteria Streptomyces tsukubaensis. FK-506 inhibits signal transduction and interleukin-2 transcription in CD4+ T helper lymphocytes, and is mainly used after allogenic organ transplantation to reduce organ rejection. Side effects of FK-506 treatment include nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension.
Clonality
Monoclonal
Host
Mouse
Isotype
IgM
Description
Novus Biologicals Mouse FK506 Antibody (FK1) - BSA Free (NB100-62571) is a monoclonal antibody validated for use in ELISA. All Novus Biologicals antibodies are covered by our 100% guarantee.
Applications for FK506 Antibody (FK1) - BSA Free
Application
Recommended Usage
ELISA
1:100-1:2000
Formulation, Preparation, and Storage
Purification
IgM purified
Formulation
TBS
Format
BSA Free
Preservative
<0.1% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: FK506
FK506 antigen is a novel macrolide with similar but more potent immunosuppressant activity than cyclosporine. FK506 is used for primary or rescue immunosuppression in patients after solid organ transplantation. Clinically relevant FK506 side effects are nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension. Most of these side effects are more closely related to FK 506 blood levels than dosage; therefore therapeutic drug monitoring (TDM) of FK506 levels is a prerequisite for therapy. Whole blood is the matrix of choice for FK506 TDM. The whole blood target level range aimed for in clinical practice is between 3.0 and 20.0 ng/ml and depends on the patient's liver function, the type of organ transplanted and the time after transplantation.
Alternate Names
C44H69NO12;FK-506;Fujimycin;Tacrolimus
Additional FK506 Products
Product Documents for FK506 Antibody (FK1) - BSA Free
Product Specific Notices for FK506 Antibody (FK1) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...